Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 219,570 shares of the medical research company’s stock after selling 402 shares during the period. Dimensional Fund Advisors LP owned 0.75% of Bio-Rad Laboratories worth $70,900,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Victory Capital Management Inc. grew its holdings in Bio-Rad Laboratories by 48.7% in the fourth quarter. Victory Capital Management Inc. now owns 17,671 shares of the medical research company’s stock valued at $5,706,000 after purchasing an additional 5,790 shares during the period. Lecap Asset Management Ltd. purchased a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at $1,590,000. Comerica Bank acquired a new stake in shares of Bio-Rad Laboratories during the 3rd quarter worth $11,054,000. Thompson Siegel & Walmsley LLC raised its position in shares of Bio-Rad Laboratories by 6.3% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 312,583 shares of the medical research company’s stock worth $112,046,000 after buying an additional 18,419 shares during the period. Finally, Caxton Associates LP acquired a new position in Bio-Rad Laboratories in the third quarter valued at $668,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on BIO shares. UBS Group reduced their price objective on Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Royal Bank of Canada decreased their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Finally, Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $400.00 to $365.00 in a research report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $461.00.

Insiders Place Their Bets

In other news, EVP Michael Crowley sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the completion of the sale, the executive vice president now owns 6,942 shares of the company’s stock, valued at $2,332,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 17.06% of the stock is owned by company insiders.

Bio-Rad Laboratories Price Performance

BIO opened at $287.21 on Friday. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $431.79. The company has a current ratio of 6.57, a quick ratio of 4.89 and a debt-to-equity ratio of 0.13. The firm has a market cap of $8.19 billion, a price-to-earnings ratio of -27.72 and a beta of 0.94. The company has a fifty day simple moving average of $304.28 and a 200 day simple moving average of $314.22.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Tuesday, May 7th. The medical research company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.25. The business had revenue of $610.82 million for the quarter, compared to analyst estimates of $619.09 million. Bio-Rad Laboratories had a positive return on equity of 3.59% and a negative net margin of 12.37%. The company’s revenue for the quarter was down 9.8% compared to the same quarter last year. During the same period in the previous year, the company earned $3.34 earnings per share. Equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.